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1. Background 
 
1.1. Risk Assessment and the Quality by Design 
The QbD approach is a holistic, systematic, knowledge and risk based methodology of 
pharmaceutical development approach, which is proactive and focuses on profound preliminary 
design [1][2]. It represents the main stream of the pharmaceutical technological formulation 
development nowadays [3]–[7]. QbD has several steps, which are described in the relevant 
guidelines of the International Council of Harmonisation (ICH), namely in the ICH Q8R2, Q9, Q10 
papers [8]–[10]. The implementation of QbD in the manufacturing of medicinal products is often 
called the “GMP of the 21st century”; regulatory authorities strongly force the pharmaceutical 
industry to apply this strategic planning approach [6] [7]. The adaptation and application of this 
methodology into the early research phases within the R & D activities holds many advantages, 
as mentioned in our previous papers. QbD based early development brings scientific results 
closer to the practical requirements and has a facilitating effect on industrial scale up and 
product transfer to the market. The main elements of QbD (Fig. 1) are: (1) the definition of the 
Quality Target Product Profile (QTPP), (2) the identification of the quality attributes and the 
selection of the Critical Quality Attributes (CQAs) related to the target product, (3) the prior 
selection of the production method and the identification of the Critical Process Parameters 
(CPPs), (4) performing of the initial Risk Assessment (RA). The results of RA will be the ordered 
CQAs and CPPs according to their calculated risk severity. The next step is the (5) setting up of 
the Design of Experiments (DoE) based on the highly risk related factors calculated previously in 
the RA step. This DoE is generally a factorial design and the aim is to determine the process and 
product Design Space (DS) (6). This DS means a multidimensional space and is determined by 
ranges of process elements and material attributes. Then it is needed to determine the Control 
Strategy (7), followed by the evaluation of the possibilities of Continuous Improvement (8). RA is 
a key element in general, and it is especially advantageous in the case of complex drugs (e.g. 
peptides) and/or carrier systems of special risk (e.g. nano-delivery systems). 
 
1.2.  Peptide drug delivery and new formulation possibilities 
The interest in the pharmaceutical technology utilizing therapeutic peptides in the 
treatment of a variety of diseases has dramatically increased over the past few years. However, 
these peptides suffer from several drawbacks, including metabolic liability, poor permeability 
across biological barriers, and fast hepatic clearance and subsequent inherent short half-lives, 
which all lead to the low bioavailability of such drugs. Hence, peptide administration is usually 
limited to parenteral routes such as subcutaneous (SC), intravenous (IV), and intramuscular (IM) 
administration, which are regarded as invasive routes associated with many downsides leading 
to insufficient patient adherence. Thus, a patient friendly non-invasive route of administration 
such as the oral route is desired in order to overcome the various drawbacks associated with the 
invasive delivery route. However, an orally administered peptide drug encounters numerous 
formidable obstacles, including chemical and enzymatic instability in addition to the limited 
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ability to traverse biological barriers [13]. Besides these barriers, the stability of the peptide 
drug during formulation and storage is a crucial aspect to be investigated when developing a 
peptide delivery system as peptides are sensitive drugs that can be damaged or become 
inactivate almost in every step of the production method [14]. 
The selected drug for this case study is Liraglutide, a fatty acid modified glucagon like 
peptide -1 (GLP1), which shares 97% amino acid sequence identity with human GLP-1, and is 
produced by recombinant technologies using yeast. This peptide drug was approved for the 
treatment of type 2 diabetes mellitus (T2DM) [15], and Novo Nordisk has recently begun 
marketing it for the chronic weight management for obese or overweight adults who have 
associated comorbidities, such as hypertension, diabetes and dyslipidemia [16]. Since Liraglutide 
is still delivered parenterally, the oral route should be aimed at, providing the patient friendly 
administration in addition to mimicking the physiological route of GLP-1 from intestine to 
circulation. Still, enhancing the oral bioavailibity of Liraglutide presents an interesting challenge 
and the development of a novel oral Liraglutide delivery system is regarded as a high risk and 
high reward process.  
Tremendous efforts have been devoted over the past decades to the oral administration 
of antidiabetic peptides. Based on our previous review and the evaluation of recently published 
papers in the field of antidiabetic peptide oral delivery [17][18], it can be concluded that among 
several techniques to improve antidiabetic peptide oral bioavailability, much of the success was 
recorded when using polymeric nanoparticles (NPs). And among the numerous polymers used to 
obtain polymeric NPs, poly lactic-co-glycolic acid (PLGA) is the most widely used one, as an FDA 
approved biodegradable and biocompatible synthetic polymer [19]. PLGA NPs were found to be 
successful in the protection of peptides from harsh environment in the gastrointestinal tract 
(GIT), thus enhancing stability, in addition to other merits of nanocarrier systems, which can all 
lead to improving the oral bioavailabity of these drugs as in insulin, GLP1 or its analogs [18], 
[20]–[22]. 
The aim of this study was to evaluate the role of RA in the case of the development of a 
Liraglutide drug delivery system for oral administration. Based on a careful collection, selection 
and evaluation of the relevant literature together with the previous developments of the 
research group in this field [7][23][24], we aimed to set up a strategic flow chart with proposed 
RA function and decision steps. The selected pilot study focused on novel Liraglutide loaded 
PLGA NPs prepared by means of the double emulsion solvent evaporation method and the 
application of the QbD concept in order to optimize the formulation by evaluating the effect of 
different formulation and process parameters on the quality of the prepared PLGA NPs.  
 
 
2. Materials and Methods 
2.1 Knowledge space development 
 
4 
 
According to the QbD nomenclature, the collection and systematization of the relevant scientific 
literature and experience from the previous research is called “knowledge space development”. 
The methodology was the analysis of the relevant scientific literature, structural development of 
data-collection. Modern quality management tools were used for visualization, such as 
preparation of Ishikawa diagrams [25] and building up of flow charts for process description and 
systemic evaluation [26].   
 
2.2 Definition of QTPP and selection of CQAs, CMAs and CPPs  
 
The QTPP forms the basis of product development design. It should include patient-relevant 
product performance and characteristics related to the aimed therapeutic or clinical use. 
Considerations for QTPP selection are described in the ICH Q8R2 guideline, e.g. the route of 
administration, dosage form, delivery system, pharmacokinetic and other product quality 
criteria (e.g. sterility, stability and drug release), etc. The QTPP is always unique depending on 
the target. Those factors which have critical influence on the QTPP linked with safety, quality or 
efficacy are CQAs. CQAs are generally associated with the drug substance, excipients, 
intermediates (in-process materials) and drug product. A CQA is a physical, chemical, biological, 
or microbiological property or characteristic of the output material (product) that should be 
within an appropriate limit, range, or distribution to ensure the desired product quality. CQAs 
are connected strictly to the product. The selection of CQAs needs carful design and a holistic 
view of the formulation development. CMAs are critical material attributes, physical, chemical, 
biological, or microbiological properties or characteristics of an input material [27]. CPPs are 
process parameters whose variability has a critical effect on the aimed product performance. 
CPPs and CMAs are linked to the production/formulation process. The CQA, CMA and CPP 
selection is based on prior knowledge, previous practical investigations and data from the 
relevant literature.  
 
2.3 Risk Assessment 
 
Risk Assessment aids in identifying which material attributes and process parameters potentially 
have an effect on product CQAs (ICH Q8R2). On the basis of prior knowledge and initial 
experimental data, RA tools can be used to identify and rank parameters (e.g. process, 
equipment and input materials) with the potential of impacting on final product quality. The 
initial RA was performed with Lean QbD Software (Lean QbD® Software, QbD Works LLC. USA, 
CA, Fremont) to evaluate the risks and get the Risk Priority Number (RPN) data. First, the 
interdependence rating was performed between CQAs and CMAs, CQAs and CPPs on a three-
level scale and categorized as “high” (H), “medium,” (M) or “low” (L). After the interdependence 
rating, an occurrence rating related to the selected CQAs, CMAs and CPPs was also made. The 
whole risk estimation resulted in calculated and ranked severity scores of CQAs, CMAs and CPPs, 
presented in Pareto charts generated by the software. The software also generates the relative 
occurrence-relative severity chart, depicting the critical factors in four different groups 
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according to their estimated occurrence and severity (or the degree of their impact if they 
occur) estimated as the result of the RA. This affords a different presentation mode of the RA 
results. In this manner the upper right corner of the generated figure needs the highest 
attention as it represents those critical factors which have the highest risk of occurrence and 
have great impact on quality.   
Generally, RA results show the factors with the highest impact on product quality, which are 
usually the key elements of the systemic designed experiments in practice. 
 
Results 
 
2.1.  Theoretical evaluation of the risk assessment based oral peptide drug formulation 
development - GENERAL CONSIDERATIONS 
Oral peptide drug delivery has several challenges and many risks because peptide drugs are 
more complex and heterogeneous in nature than chemical drugs [28][29][30]. Every product is 
unique with several risks related [31]. Also, the European Medicine Agency (EMA) says that: 
“Biological products possess such a large number of quality attributes that it might not be 
possible to fully evaluate the impact on safety and efficacy of each one. Risk assessments can be 
performed to rank or prioritize quality attributes”. So RA is a key element in the formulation of 
biological and even in the oral peptide delivery preparations. Figure 2 presents the collected 
potential risk factors which should be taken into consideration when developing a new oral 
peptide dosage form (Fig. 2, A). 
It is very important to note that besides the guidelines which describe the classical QbD (ICH 
Q82R, Q9 and Q10), an extension has to be made with the ICH Q11 guideline [32] about the 
development and manufacturing of drug substances as shown in Figure 2, part B., since special 
attention needs to be paid when the active pharmaceutical ingredient is biological, like peptide. 
In the next step of the knowledge space development phase of this study, the following 
Ishikawa diagram was set up as a result (Fig. 3.). The Ishikawa diagram, as a quality management 
tool, can help to explore the cause and effect relationships. The diagram marks all the 
influencing factors related to peptide formulation for oral delivery in a detailed manner. These 
influencing factors can be the potential risks or CQAs, CPPs depending on the aimed formula. On 
the other hand, in the case of biologicals, the effect of the CQAs and CPPs on the QTPP are more 
difficult to understand, and the interactions are more complex with other risk aspects related to 
the safety, efficacy, immunogenicity, pharmacokinetics, bioactivity, etc. of the final drug product 
[33]. Rathore A. gives a thorough description of the relationships between the quality criteria of 
the biotechnology product and their safety and efficacy [34]. On the other hand, the monoclonal 
antibody formulation study by Awotwe-Otoo et al. draws attention to the special elements of a 
biologic QTPP, such as elements regarding the reconstitution of previously lyophilized formula 
(e.g. reconstitution time, isotonicity, aggregation, etc.), which underlines the need for complex 
and careful thinking in this field [35].  
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Besides the several different CQAs of a peptide formula, the formulation process development 
could have many additional problems, i.e. the technology transfer may be difficult due to the 
sensitive nature of the peptide drug as small changes in either the formulation composition or in 
the manufacturing steps can have great effect on the final quality [36] [37]. 
The following flow chart illustrates the suggested decisions and their order when formulating a 
new dosage form containing a peptide drug (Fig. 4). 
The therapeutic target area (“unmet clinical need”) should be defined first, which gives the main 
framework for the API selection. The peptide type API has to be characterized next, namely the 
physio-chemical properties, therapeutic activity profile, physical, chemical or structural stability, 
impurities, and the fact whether a surface modification is needed or not in order to fit the 
purpose. In connection with API profile building, it is required to define the desired therapeutic 
targeted place, either local or systemic. If the aimed effect is local, the drug size is not critical, 
immunogenicity is reduced, and there is no need for using permeability enhancers. If the new 
peptide formula is designed to have a systemic effect, the size is critical because of absorption, 
and the risk of immunogenicity is also increased. Immunogenicity is one of the most critical 
elements, so each aspect that has an influence or a potential influence on it needs special 
attention. Excipients could also be risk factors, as it is necessary to use permeability enhancers 
for better absorption, and enzyme inhibitors in order to protect the peptide from inactivation. 
This is also the point where the administration route of the planned new dosage form has to be 
decided. If the oral route is targeted, the following characteristics could be critical, for example: 
size, charge or electrostatic interactions, surface polarity, bioadhesive properties, lipophilicity, 
PEGylation, surface ligands. The dosage form selection is also part of the development design, 
and will be part of the QTPPs at the end as well. Depending on the targeted dosage form (e.g. 
conventional capsule, tablet like solid forms or emulsion, suspension, liquid formulas etc.), 
special considerations have to be made regarding excipients (permeation enhancers, protease 
inhibitors, enteric coating materials, artificial proteins, protective antibodies, etc.) and the 
proper production process has to be selected. Related to that phase of the design, the 
preliminary definition of other requirements is essential. These requirements include the 
dissolution profile, stability, impurities, permeability related characteristics, etc. The production 
process is also highly critical in the case of peptide formulation, due to their sensitivity. In this 
consideration, the selected manufacturing process has to be evaluated carefully from the risky 
aspects and the CPPs have to be selected. Other decisions should be made concerning 
regulatory and industrial expectations. From these aspects, costs planning can be a critical point 
of decision as there could be great differences in the marketing authorization costs between an 
originator and a biosimilar medicinal product.  
The left part of Figure 4 will generally give the basis of the QTPP definition, and the other 
sections of the chart could give the basis of the CQA and CPP selection for the different targeted 
peptide formulations. After the selection step the RA can be performed. 
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2.2. Practical implementation: Results of the risk assessment of a Liraglutide containing drug 
formulation development for oral delivery - PRACTICAL FINDINGS 
The study presented below is intended to show how the previously introduced risk based 
theoretical model can be applied in the early design phase of peptide drug containing 
formulation development. Based on reviewing the most relevant strategies [17], Liraglutide 
loaded PLGA NPs are to be prepared by using the double emulsion solvent evaporation method, 
well-known [38] as a suitable choice for encapsulating hydrophilic drugs, particularly protein and 
peptide drugs [39][40]. 
As shown in Figure 5, Liraglutide encapsulation via this method will be performed by first 
forming primary emulsion w1/o, where the aqueous solution of the peptide drug is added to the 
polymeric organic solution upon sonication in ice bath. This is followed by the formation of a 
double emulsion (w1/o/w2) by dispersing the primary emulsion in an external aqueous phase 
containing poly vinyl alcohol PVA as a stabilizer, with the use of sonication in ice bath. Finally, 
organic solvent evaporation results in the formation of Liraglutide loaded nanoparticles. 
According to the guideline, the initial step of this QbD based study aiming to design oral 
Liraglutide loaded PLGA NPs was to set up the QTPP as shown in Figure 6. 
Then, the proposed CQAs that could critically affect the desired QTPP were identified. This was 
followed by selecting CMAs and CPPs that may have a significant effect on the CQAs of the lira-
PLGA NPs, and the Ishikawa fish bone diagram [41] was constructed to illustrate these potential 
formulation and process variables likely to impact the quality of the lira-PLGA NPs (Fig. 7).  
The initial RA study was achieved by means of the “Lean QbD” software. Figure 8 depicts the 
interdependence rating on the three-point scale between the selected CQAs and CMAs on the 
one hand, and CQAs and CPPs on the other hand. 
The calculated and ranked severity scores for the CQAs, CMAs and CPPs are presented in Pareto 
charts generated by the Lean QbD Software as shown in Figure 9. 
Besides, Figure 10 presents the occurrence rating of the CMAs and CPPs, and here we selected 
the most potential factors with the highest occurrence and severity rate to be subjected to 
further investigation, applying a suitable design of experiment that enables the statistical 
optimization of the Liraglutide containing nanoparticles by defining the optimal value of each 
examined variable. 
 
3. Discussion: 
The main steps and elements of oral peptide formulation development were evaluated as 
peptide type API containing formulations can be handled as high risk dosage forms due to their 
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complexity in both composition and preparation design. Initial risk assessment should be 
considered as a crucial part of the development process. 
Classic drug development works with small, chemically manufactured active substance 
molecules. Biologic drugs, such as peptides, are biologically produced large molecules.  
Compared with conventional small drug formulation, peptide containing dosage form 
development has many challenges. For example, oral delivery systems for peptides need special 
considerations as the active agent has to be protected against digestion in the stomach and 
intestines, whereupon they become ineffective. The right technological formulation technique 
in addition to the proper selection of the excipients (permeation enhancers, protease inhibitors 
if needed, coating materials, etc.) could be the solutions to peptide stability and protection. The 
sensitivity of the biologicals should be the most focused area during their formulation 
development. In this regard, the  main findings are the following: the prior ranking of the CQAs 
and CPPs which are mainly related to stability in the peptide formulation helps in more effective 
experimental design and the prioritization of the limited development sources. The 
identification of the relative risk levels at the beginning of product development has great 
advantages in such complex formulation.  
The highly focused RA fields in peptide drug formulation are the following: (1) The drug 
substance (API), especially characteristics related to its stability and quality. (2) The 
manufacturing process, also related to the API and product stability. Small changes in the 
production process could have a great effect on quality thus influencing the safety, efficacy and 
side effects related to the therapeutic application. These are strongly connected to the 
immunogenicity aspects (3). 
Regarding the RA based study of Liraglutide encapsulated in PLGA NPs system prepared by 
double emulsion solvent evaporation technique for enhancing the oral bioavailability of this 
peptide drug, the QTPP was set up as presented in Figure 6 based on prior knowledge regarding 
the peptide delivery, PLGA NPs formulation and methods of preparation, in addition to our 
initial experimental data. This was followed by the identification of CQAs, namely: particle size, 
zeta potential, polydispersity index (PDI), encapsulation efficiency (EE) and drug loading (DL). 
Then, initial RA was performed by identifying the CMAs and CPPs (regarding the double 
emulsion evaporation method) that may have a high risk of impacting the CQAs of the 
Liraglutide loaded PLGA nanoparticles [42]. Here, the Ishikawa fish bone diagram was 
constructed to configure the risk analysis process for defining the cause and effect relationship 
between the significant variables and the CQAs of the desired lira-PLGA NPs [43], and it can be 
seen from Figure 7 that six main formulation (outer aqueous phase, inner aqueous phase, 
organic phase) and process (homogenization, centrifugation, freeze-drying) causes were 
identified. Further RA using Lean QbD software showed that the most highly influential CPP (Fig. 
8B, 9C, 10B) is sonication time, while the most highly influential CMAs (Fig. 8A, 9B, 10A) are 
polymer concentration, drug concentration, stabilizer concentration, cryoprotectant type, 
cryoprotectant concentration and external aqueous phase to organic phase ratio  w2/o.  
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To optimize process and formulation parameters, all these potential parameters will be 
subjected to further investigation with the use of a screening statistical design of experiment 
DOE [44] in order to minimize their risk to a low level by controlling theses variables in a specific 
accepted range in order to obtain design space, thus assuring the desired CQAs values, to 
comply with the QTPP. 
4. Conclusion: 
Several challenges and many risks are entailed in formulating dosage forms containing peptide 
drugs, which are more complex and heterogeneous in nature than chemical drugs. Thus, it is 
advisable to apply QbD based formulation development in order to save time and effort by 
directing the effort toward building the quality in each step of peptide delivery system 
development, which includes RA as an initial part of this QbD based process. This RA focused 
approach of the peptide pharmaceutical formulation development is essential as it results in 
ranked and prioritized risk factors, thereby leading to an effective formulation development. 
This study can help researchers to implement RA focused thinking and the QbD approach in 
their peptide formulation development if they follow the general steps of decisions presented 
previously. In our pilot study, QbD oriented development was successfully implemented to gain 
understanding of critical parameters influencing the quality of the Liraglutide loaded PLGA NPs. 
Furthermore, the next step will be the application of a reliable and robust statistical DOE to 
investigate the effect of the most critical factors on CQAs with minimum number of runs, then 
determining the best optimum level of each variable which should be used to prepare an 
optimized formulation that assures the required CQAs. 
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Figure 1: Elements of QbD in pharmaceutical development and their interrelation with the relevant 
ICH guidelines 
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Figure 2. Potential risks to be considered in the development of a new oral peptide containing drug (A) and steps of the extended QbD method (B) 
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Figure 3. Ishikawa diagram for evaluating risks in general, related to the quality of an oral peptide drug development  
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 Figure 4: Flow chart of decision steps involving risk assessment for the development of a peptide 
formulation 
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Figure 5: Schematic illustration of the double emulsion solvent evaporation technique for the 
preparation of Liraglutide loaded PLGA NPs. 
 
Figure(s)
1 
 
 
 
 
Figure 6: Defining the QTPP for Liraglutide loaded PLGA NPs 
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Figure 7: Formulation and process parameters affecting the CQAs of lira-PLGA NPs 
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Figure 8: RA interdependence ratings: (A) the interdependence rating matrix between the selected 
CQAs and CMAs, and (B) between the CQAs and CPPs 
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Figure 9: Pareto charts A- Estimated severity scores of the proposed CQAs, B- Estimated severity 
rating of the proposed CMAs, C- Estimated severity rating of the proposed CPPs 
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 Figure 10: Relative Occurrence/Relative Severity of  A- proposed CMAs, B- proposed CPPs 
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